Editas Medicine Inc
NASDAQ:EDIT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Delivery Hero SE
XETRA:DHER
|
DE |
|
China Aluminum Cans Holdings Ltd
HKEX:6898
|
CN |
|
B
|
Bank of Ireland Group PLC
LSE:BIRG
|
IE |
|
N
|
Nantong Jiangshan Agrochemical & Chemicals Co Ltd
SSE:600389
|
CN |
|
Phoenix Tours International Inc
TWSE:5706
|
TW |
|
S
|
STMicroelectronics NV
LSE:0INB
|
CH |
|
C
|
CSE Global Ltd
SGX:544
|
SG |
|
B
|
Bergman & Beving AB
STO:BERG B
|
SE |
|
A
|
Automotive Stampings and Assemblies Ltd
NSE:ASAL
|
IN |
|
China Aviation Oil (Singapore) Corporation Ltd
SGX:G92
|
SG |
|
T
|
Tamar Petroleum Ltd
TASE:TMRP
|
IL |
Editas Medicine Inc
Non-Reccuring Items
Editas Medicine Inc
Non-Reccuring Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Non-Reccuring Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Editas Medicine Inc
NASDAQ:EDIT
|
Non-Reccuring Items
-$60.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Non-Reccuring Items
-$5.9B
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Non-Reccuring Items
-$1.8B
|
CAGR 3-Years
24%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Non-Reccuring Items
-$7.1B
|
CAGR 3-Years
-144%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-61%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Non-Reccuring Items
-$512m
|
CAGR 3-Years
-59%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-72%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Non-Reccuring Items
-$297m
|
CAGR 3-Years
17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-32%
|
|
Editas Medicine Inc
Glance View
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 264 full-time employees. The company went IPO on 2016-02-03. The firm is focused on developing transformative gene editing medicines to treat a range of serious diseases. The company has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The firm is focused on both in vivo gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, and ex vivo gene-edited cell medicines, in which cells are edited with its technology. The firm's gene editing medicine programs include EDIT-101, EDIT-102, EDIT-103, EDIT-301 and EDIT-202.
See Also
What is Editas Medicine Inc's Non-Reccuring Items?
Non-Reccuring Items
-60.7m
USD
Based on the financial report for Dec 31, 2025, Editas Medicine Inc's Non-Reccuring Items amounts to -60.7m USD.
What is Editas Medicine Inc's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 1Y
-396%
Over the last year, the Non-Reccuring Items growth was -396%.
